Published: 10 May 2021
Author(s): Adi Elias, Yael Morgenstern, Eyal Braun, Benjamin Brenner, Inna Tzoran
Issue: July 2021
Section: Letter to the editor

Atrial fibrillation (AF) is the most prevalent sustained arrhythmia. Benefits of anticoagulation therapy in reducing the risk of ischemic stroke in the majority of patients with AF are well-established [1,2]. AF incidence is suggested to be increased in cancer patients and they are hypothesized to be at a higher risk of ischemic stroke [3]. The efficacy of prophylactic anticoagulation in cancer patients has lately been assessed in several studies, reporting divergent results [4,5]. In the last decade, four direct oral anticoagulants (DOACs) designed to reduce the risk of stroke and systemic embolism have been approved.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.